LEADERSHIP TEAM ARTICLES
LEADERSHIP TEAM WEBINARS
By Dr. Kazem Kazempour and Hana Mekonnen
Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause
By Dr. Kazem Kazempour and Hana Mekonnen
A phase I trial of RX-0201 (Archexin; akt -1 Antisense) in patients with advanced cancer
By Dr. Kazem Kazempour
Impact of imbalance in stratification factor on probability of type I error
By Dr. Kazem Kazempour
Pain Relief Methods after Thoracotomy
By Shide Badri
Webinar: Non-Inferiority trial designs to establish effectiveness, when to use it? What is the Margin, how to set it, and its impact on sample size/power?
Presented by: Dr. Kazem Kazempour
Discussion Points:
In November 2016, FDA finalized the guideline for Non-Inferiority (NI) trial design to establish effectiveness.
The draft of this guideline and several similar guidelines were published in 2010, and in most part were in use prior to being finalized. The new guidance has replaced the drafted guidance(s) for industry.
In this talk, we discussed when and why an Non-Inferiority trial is needed, how to design and interpret the results of a NI study so that it can be used as an FDA acceptable, adequate and well-controlled trial to establish effectiveness. Lastly, we discussed the margins used in these types of studies and their impact on the size and power of the study.